India’s CRDMO sector poised for rapid growth despite challenges
India’s Contract Research, Development, and Manufacturing Organization (CRDMO) sector is poised for exponential growth in the coming years, driven by global pharmaceutical realignments and cost advantages. According to a report by BCG, the sector is projected to expand from $3â3.5 billion to $22â25 billion by 2035. This remarkable growth is attributed to India’s strengths in small molecule manufacturing, as well as emerging capabilities in biologics, antibody-drug conjugates (ADCs), and gene therapies.
The CRDMO sector plays a vital role in the pharmaceutical industry, providing contract services to pharmaceutical companies, biotech firms, and research institutions. These organizations outsource their research, development, and manufacturing needs to CRDMOs, which in turn, leverage their expertise, infrastructure, and cost advantages to deliver high-quality products and services.
India has emerged as a preferred destination for CRDMOs due to its favorable business environment, skilled workforce, and cost competitiveness. The country’s pharmaceutical industry has grown significantly over the years, driven by government initiatives, investments, and partnerships. The government’s “Pharma Vision 2020” program aims to make India a global hub for pharmaceutical research and development, manufacturing, and exports.
One of the key strengths of India’s CRDMO sector is its small molecule manufacturing capabilities. Indian CRDMOs have built expertise in manufacturing active pharmaceutical ingredients (APIs), intermediates, and finished dosage forms, catering to a wide range of therapeutic areas, including oncology, cardiovascular, and central nervous system disorders. Several global pharmaceutical companies have already established partnerships with Indian CRDMOs, leveraging their capabilities and expertise to expand their product portfolios.
In addition to small molecule manufacturing, Indian CRDMOs are also making significant progress in biologics, ADCs, and gene therapies. Biologics, which include proteins, peptides, and vaccines, are a growing segment in the pharmaceutical industry, driven by their increasing adoption for treating complex diseases such as cancer, diabetes, and autoimmune disorders. Indian CRDMOs are developing capabilities in biologics manufacturing, including process development, scale-up, and commercial production.
ADCs, which combine a targeted therapeutic agent with a cytotoxic drug, are another area of focus for Indian CRDMOs. ADCs are designed to selectively target cancer cells, reducing the risk of toxicity and improving patient outcomes. Indian CRDMOs are developing expertise in ADC manufacturing, including process development, scale-up, and commercial production.
Gene therapies, which involve the transfer of genetic material to treat diseases, are a relatively new and rapidly evolving area. Indian CRDMOs are investing in gene therapy development, manufacturing, and commercialization, leveraging their expertise in biologics and small molecule manufacturing.
Despite the significant growth prospects, the CRDMO sector in India faces challenges, including regulatory hurdles, intellectual property concerns, and capacity constraints. To overcome these challenges, Indian CRDMOs must ensure compliance with global regulatory standards, invest in research and development, and build partnerships with global pharmaceutical companies.
The COVID-19 pandemic has also posed significant challenges to the CRDMO sector, including supply chain disruptions, workforce shortages, and regulatory delays. However, the sector has demonstrated its resilience, with many Indian CRDMOs adapting quickly to the new reality and finding innovative solutions to maintain operations and deliver products.
In conclusion, India’s CRDMO sector is poised for rapid growth in the coming years, driven by global pharmaceutical realignments and cost advantages. The sector’s strengths in small molecule manufacturing, emerging capabilities in biologics, ADCs, and gene therapies, and favorable business environment make it an attractive destination for global pharmaceutical companies. While challenges remain, Indian CRDMOs must continue to innovate, invest in research and development, and build partnerships to realize their growth potential.
Source:
https://youtu.be/M5Z32CkzXnY
